ADENOSINE THERAPEUTICS, LLC

Basic Information

310 FOURTH STREET NE
SUITE 201
CHARLOTTESVILLE, VA, 22902

Company Profile

n/a

Additional Details

Field Value
DUNS: 1016760
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Adenosine A2A receptor antagonists for the treatment of cocaine addiction

    Amount: $104,783.00

    DESCRIPTION (provided by applicant): Selective antagonists of A2A adenosine receptors (A2AR) are thought to have potential for the treatment of addictive disorders, including cocaine addiction. This p ...

    SBIR Phase I 2007 Department of Health and Human Services
  2. A2A Adenosine Receptors and Equine Sepsis

    Amount: $296,000.00

    Endotoxemia (Sepsis) affects horses of all breeds and ages and is the leading causes of death in adult horses and foals. Consequently, its economic impact on the equine industry in the United States i ...

    SBIR Phase II 2006 Department of Agriculture
  3. A2A AR Agonists as Adjunct Therapy Against S. aureus Sepsis

    Amount: $132,798.00

    DESCRIPTION (provided by applicant): This is a phase I STTR application to study the efficacy of selective adenosine A2A receptor (A2AR) agonists developed in the laboratories of Adenosine Therapeutic ...

    STTR Phase I 2006 Department of Health and Human Services
  4. A2a AR Agonists for Rheumatoid Arthritis

    Amount: $137,603.00

    DESCRIPTION (provided by applicant): This is the first revision of a phase I STTR proposal to develop new therapies for the treatment of rheumatoid arthritis (RA). It is collaboration between a biotec ...

    STTR Phase I 2006 Department of Health and Human Services
  5. Safety of A2A Adenosine Agonist for Treatment of Sepsis

    Amount: $1,276,772.00

    DESCRIPTION (provided by applicant): ATL146e is a synthetic small molecule developed by Adenosine Therapeutics, LLC (ATL) that acts as a selective agonist of the adenosine A2A receptor. ATL146e, steri ...

    STTR Phase I 2006 Department of Health and Human Services
  6. Antagonists of A2B Adenosine Receptors for Asthma

    Amount: $1,440,610.00

    DESCRIPTION (provided by applicant): This is a Phase II SBIR proposal to develop a new therapy for the treatment of asthma. The desired outcome will be the identification of a therapeutic candidate to ...

    SBIR Phase II 2006 Department of Health and Human Services
  7. A2a Adenosine Agonists for Diabetic Nephropathy

    Amount: $147,326.00

    DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) accounts for approximately 40% of the cases of renal failure requiring dialysis or transplantation. Moreover, diabetic nephropathy is ass ...

    STTR Phase I 2005 Department of Health and Human Services
  8. A2a Adenosine Blockers for Parkinson's Disease

    Amount: $139,176.00

    DESCRIPTION (PROVIDED BY APPLICANT): Selective antagonists of A2A adenosine receptors have proven to be effective for the treatment of Parkinson's disease (PD) both in animal models and in a human tri ...

    STTR Phase I 2005 Department of Health and Human Services
  9. A2a Adenosine Agonist Cardiac Reperfusion Injury

    Amount: $288,277.00

    DESCRIPTION (provided by applicant): Founded in 1999, Adenosine Therapeutics LLC (ATL) is a drug discovery and development company that has developed a family of potent and selective adenosine A2A re ...

    SBIR Phase I 2005 Department of Health and Human Services
  10. Novel A2A Adenosine Agonists in Vascular Protection

    Amount: $1,247,577.00

    DESCRIPTION (provided by applicant): This is a phase II SBIR proposal to develop a new drug eluting stent to prevent restenosis. It is a 3-way collaboration between Adenosine Therapeutics, LLC, Setago ...

    STTR Phase II 2004 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government